145 related articles for article (PubMed ID: 22833925)
21. Immunogenicity of an adeno-vector vaccine expressing the F protein of a respiratory syncytial virus manufactured from serum-free suspension culture.
Shao HY; Hsu HS; Yu SL; Wu SR; Hu KC; Chang CK; Liu CC; Chow YH
Antiviral Res; 2016 Jun; 130():27-35. PubMed ID: 27001351
[TBL] [Abstract][Full Text] [Related]
22. Influence of fiber detargeting on adenovirus-mediated innate and adaptive immune activation.
Schoggins JW; Nociari M; Philpott N; Falck-Pedersen E
J Virol; 2005 Sep; 79(18):11627-37. PubMed ID: 16140740
[TBL] [Abstract][Full Text] [Related]
23. Covalent decoration of adenovirus vector capsids with the carbohydrate epitope αGal does not improve vector immunogenicity, but allows to study the in vivo fate of adenovirus immunocomplexes.
Kratzer RF; Espenlaub S; Hoffmeister A; Kron MW; Kreppel F
PLoS One; 2017; 12(5):e0176852. PubMed ID: 28472163
[TBL] [Abstract][Full Text] [Related]
24. Comparative Study of Adeno-associated Virus, Adenovirus, Bacu lovirus and Lentivirus Vectors for Gene Therapy of the Eyes.
Kalesnykas G; Kokki E; Alasaarela L; Lesch HP; Tuulos T; Kinnunen K; Uusitalo H; Airenne K; Yla-Herttuala S
Curr Gene Ther; 2017; 17(3):235-247. PubMed ID: 28982327
[TBL] [Abstract][Full Text] [Related]
25. A Recombinant Chimeric Ad5/3 Vector Expressing a Multistage Plasmodium Antigen Induces Protective Immunity in Mice Using Heterologous Prime-Boost Immunization Regimens.
Cabrera-Mora M; Fonseca JA; Singh B; Zhao C; Makarova N; Dmitriev I; Curiel DT; Blackwell J; Moreno A
J Immunol; 2016 Oct; 197(7):2748-61. PubMed ID: 27574299
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity of adenovirus vaccines expressing the PCV2 capsid protein in pigs.
Li D; Du Q; Wu B; Li J; Chang L; Zhao X; Huang Y; Tong D
Vaccine; 2017 Aug; 35(36):4722-4729. PubMed ID: 28755834
[TBL] [Abstract][Full Text] [Related]
27. Evolving lessons on nanomaterial-coated viral vectors for local and systemic gene therapy.
Kasala D; Yoon AR; Hong J; Kim SW; Yun CO
Nanomedicine (Lond); 2016 Jul; 11(13):1689-713. PubMed ID: 27348247
[TBL] [Abstract][Full Text] [Related]
28. The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens.
Schirmbeck R; Reimann J; Kochanek S; Kreppel F
Mol Ther; 2008 Sep; 16(9):1609-16. PubMed ID: 18612271
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the immune response elicited by vaccination with viral vectors encoding FMDV capsid proteins and boosted with inactivated virus.
Romanutti C; D'Antuono A; Palacios C; Quattrocchi V; Zamorano P; La Torre J; Mattion N
Vet Microbiol; 2013 Aug; 165(3-4):333-40. PubMed ID: 23683999
[TBL] [Abstract][Full Text] [Related]
30. An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization.
Lemiale F; Asefa B; Ye D; Chen C; Korokhov N; Humeau L
Vaccine; 2010 Feb; 28(8):1952-61. PubMed ID: 20188251
[TBL] [Abstract][Full Text] [Related]
31. Efficient generation and amplification of high-capacity adeno-associated virus/adenovirus hybrid vectors.
Gonçalves MA; van der Velde I; Janssen JM; Maassen BT; Heemskerk EH; Opstelten DJ; Knaän-Shanzer S; Valerio D; de Vries AA
J Virol; 2002 Nov; 76(21):10734-44. PubMed ID: 12368316
[TBL] [Abstract][Full Text] [Related]
32. Viral vectors as vaccine carriers.
Ertl HC
Curr Opin Virol; 2016 Dec; 21():1-8. PubMed ID: 27327517
[TBL] [Abstract][Full Text] [Related]
33. Heterologous HIV-based lentiviral/adenoviral vectors immunizations result in enhanced HIV-specific immunity.
Asefa B; Korokhov N; Lemiale F
Vaccine; 2010 Apr; 28(20):3617-24. PubMed ID: 20051277
[TBL] [Abstract][Full Text] [Related]
34. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.
Björklund A; Kirik D; Rosenblad C; Georgievska B; Lundberg C; Mandel RJ
Brain Res; 2000 Dec; 886(1-2):82-98. PubMed ID: 11119690
[TBL] [Abstract][Full Text] [Related]
35. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
36. Viral vectors for stable transduction of human mesenchymal stem cells: systems based on adeno-associated viruses and lentiviruses.
Shakhbazau AV; Sevyaryn IN; Goncharova NV; Grinev VV; Kosmacheva SM; Potapnev MP
Bull Exp Biol Med; 2008 Oct; 146(4):531-3. PubMed ID: 19489335
[TBL] [Abstract][Full Text] [Related]
37. Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses.
Worgall S; Busch A; Rivara M; Bonnyay D; Leopold PL; Merritt R; Hackett NR; Rovelink PW; Bruder JT; Wickham TJ; Kovesdi I; Crystal RG
J Virol; 2004 Mar; 78(5):2572-80. PubMed ID: 14963160
[TBL] [Abstract][Full Text] [Related]
38. Viral vectors in malaria vaccine development.
Limbach KJ; Richie TL
Parasite Immunol; 2009 Sep; 31(9):501-19. PubMed ID: 19691555
[TBL] [Abstract][Full Text] [Related]
39. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV.
Xin KQ; Jounai N; Someya K; Honma K; Mizuguchi H; Naganawa S; Kitamura K; Hayakawa T; Saha S; Takeshita F; Okuda K; Honda M; Klinman DM; Okuda K
Gene Ther; 2005 Dec; 12(24):1769-77. PubMed ID: 16079886
[TBL] [Abstract][Full Text] [Related]
40. Development and evaluation of a novel gene delivery vehicle composed of adenovirus serotype 35.
Sakurai F
Biol Pharm Bull; 2008 Oct; 31(10):1819-25. PubMed ID: 18827334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
